A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

Active:	Yes
Cancer Type:	Multiple Myeloma	NCT ID:	NCT07266441
Trial Phases:	Phase II	Protocol IDs:	79635322MMY2001 (primary) NCI-2025-09158 2025-521976-80-00 79635322MMY2001
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Janssen Research & Development, LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT07266441

Summary

The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in
participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a
type of white blood cells called a plasma cell. Cancer is called relapsed if it comes
back after treatment and is called 'refractory' if does not respond to treatment) who
have received at least 3 prior lines of therapy.

Treatment Sites in Georgia

Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523

Doctors:

Lizamarie Bachier

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.